Telitacicept 160 mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
53	シェーグレン症候群	1

53. シェーグレン症候群

---

臨床試験数 : 305 /  薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05673993 (ClinicalTrials.gov)	April 2023	29/12/2022	A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome	A Phase ?, Multi-center, Randomized, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Subcutaneous Telitacicept in Subjects With Active Primary Sjogren's Syndrome	Primary Sjogren's Syndrome	Biological: Telitacicept 80 mg;Biological: Telitacicept 160 mg;Drug: Placebo	RemeGen Co., Ltd.	NULL	Not yet recruiting	18 Years	70 Years	All	375	Phase 3	China